Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Translational Study for Obesity Management in Mexican Adults Using the "Group Lifestyle Balance Program" (GLBOMEX)

20. maj 2016 opdateret af: Rolando Giovanni Díaz Zavala, Universidad de Sonora

Translational Study for Overweight and Obesity Management in Adults Using the "Group Lifestyle Balance Program" in Primary Care Clinics and Public Hospitals From Sonora, México

Obesity is the main modifiable risk factor for the development of chronic diseases in Mexico. Several randomized controlled trials have shown that intensive lifestyle programs are efficacious for the management of obesity. These programs include frequent sessions (14 or more contacts in the first 6 months) focused on diet and physical activity and use a behavior change protocol. In Mexico most primary care clinics and public hospitals apply traditional treatments for obesity management, which have limited effect on weight loss. This study would provide scientific evidence for an effective model for obesity management. Objective. The purpose of this study is to evaluate the effectiveness of the "Group Lifestyle Balance Program" for overweight and obesity management in adults, in primary care clinics and public hospitals from Sonora. This is a translational clinical study. Healthcare providers from the participating clinics will be trained with the Group Lifestyle Balance Program before its implementation. The primary outcome measurement is the change in body weight from baseline to 6 months and 12 months. Changes in body mass index, waist circumference, systolic and diastolic blood pressure, depression, quality of life and stress scales will be measured in patients receiving the program before and 6 and 12 months after starting the program. Additionally, biochemical parameters (fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, fasting insulin, Homeostatic Model Assessment- Insulin Resistance (HOMA-IR) and liver enzymes [Aspartate transaminase (AST), Alanine Aminotransferase (ALT)] will be evaluated from baseline to 12 months.

Studieoversigt

Status

Ukendt

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

258

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Sonora
      • Hermosillo, Sonora, Mexico, 83000
        • Centro de Promoción de Salud Nutricional (CPSN)
      • Hermosillo, Sonora, Mexico, 83000
        • Centro de Salud Urbano Dr. Domingo Olivares
      • Hermosillo, Sonora, Mexico, 83000
        • Hospital General del Estado de Sonora
      • Hermosillo, Sonora, Mexico, 83000
        • Hospital Ignacio Chávez
      • Hermosillo, Sonora, Mexico, 83180
        • Centro Avanzado de Atención a la Salud (CAAPS)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adults (>18 years of age and <65)
  • Overweight or Obese (BMI >25 kg/m2 y <50 kg/m2)
  • Availability and motivation to attend the intervention program
  • Patients who would benefit from participating in the program according to the health providers
  • Signing an informed consent

Exclusion Criteria:

  • Medical conditions affecting body weight significantly
  • Pregnancy or nursing
  • Bariatric surgery
  • Being unable to participate in regular moderate physical activity
  • Blood pressure >160 mm/Hg
  • HbA1c>9

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Group Lifestyle Balance Program

Participants will be assigned to an adaptation of the "Group Lifestyle Balance Program", a behavioral curriculum implemented in the Diabetes Prevention Program Study. The Group Lifestyle Balance Program will be provided weekly for the first 3.5 months, bi-weekly from 3.5 to 6 months and then monthly until 12 months. Health care providers will be trained for the implementation of the intervention.

Additionally, participants will attend at least one monthly visit with a nutritionist (individually).

The lifestyle objectives for participants will be as follows:

  1. To lose 5-10% of initial weight through healthy eating.
  2. To do 150 minutes of physical activity each week.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Change in body weight
Tidsramme: Change in body weight from baseline to 6 months and change in body weight from baseline to 12 months
Change in body weight from baseline to 6 months and change in body weight from baseline to 12 months

Sekundære resultatmål

Resultatmål
Tidsramme
Change in waist circumference
Tidsramme: Change in waist circumference from baseline to 6 months and change in waist circumference from baseline to 12 months
Change in waist circumference from baseline to 6 months and change in waist circumference from baseline to 12 months
Change in body fat percentage
Tidsramme: Change in body fat percentage from baseline to 6 months and change in body fat percentage from baseline to 12 months
Change in body fat percentage from baseline to 6 months and change in body fat percentage from baseline to 12 months
Change in the Beck Depression Inventory score
Tidsramme: Change in the Beck Depression Inventory score from baseline to 6 months and change in in the Beck Depression Inventory score from baseline to 12 months
Change in the Beck Depression Inventory score from baseline to 6 months and change in in the Beck Depression Inventory score from baseline to 12 months
Change in the Short Form-36 Health Survey score
Tidsramme: Change in the Short Form-36 Health Survey score from baseline to 6 months and change in the SF-36 Health Survey score from baseline to 12 months
Change in the Short Form-36 Health Survey score from baseline to 6 months and change in the SF-36 Health Survey score from baseline to 12 months
Change in the Perceived Stress Scale (PSS) -14 score
Tidsramme: Change in the Perceived Stress Scale (PSS) -14 score from baseline to 6 months and change in the Perceived Stress Scale PSS-14 score from baseline to 12 months
Change in the Perceived Stress Scale (PSS) -14 score from baseline to 6 months and change in the Perceived Stress Scale PSS-14 score from baseline to 12 months
Change in systolic and diastolic blood pressure
Tidsramme: Change in systolic and diastolic blood pressure from baseline to 6 months and change in systolic and diastolic blood pressure from baseline to 12 months
Change in systolic and diastolic blood pressure from baseline to 6 months and change in systolic and diastolic blood pressure from baseline to 12 months
Change in fasting glucose
Tidsramme: Change in fasting glucose from baseline to 12 months
Change in fasting glucose from baseline to 12 months
Change in total cholesterol
Tidsramme: Change in total colesterol from baseline to 12 months
Change in total colesterol from baseline to 12 months
Change in LDL-cholesterol
Tidsramme: Change in LDL-cholesterol from baseline to 12 months
Change in LDL-cholesterol from baseline to 12 months
Change in HDL-cholesterol
Tidsramme: Change in HDL-cholesterol from baseline to 12 months
Change in HDL-cholesterol from baseline to 12 months
Change in triglycerides
Tidsramme: Change in triglycerides from baseline to 12 months
Change in triglycerides from baseline to 12 months
Change in fasting insulin
Tidsramme: Change in fasting insulin from baseline to 12 months
Change in fasting insulin from baseline to 12 months
Change in HOMA-IR
Tidsramme: Change in HOMA-IR from baseline to 12 months
Change in HOMA-IR from baseline to 12 months
Change in liver enzymes [AST and ALT]
Tidsramme: Change in liver enzymes [AST and ALT] from baseline to 12 months
Change in liver enzymes [AST and ALT] from baseline to 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Rolando G Díaz, Ph.D., Universidad de Sonora

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. september 2015

Primær færdiggørelse (Forventet)

1. april 2017

Studieafslutning (Forventet)

1. april 2017

Datoer for studieregistrering

Først indsendt

25. august 2015

Først indsendt, der opfyldte QC-kriterier

28. august 2015

Først opslået (Skøn)

2. september 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

23. maj 2016

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

20. maj 2016

Sidst verificeret

1. maj 2016

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • DPPMEX-077

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Group Lifestyle Balance Program

Abonner